Comparative Pharmacology
Head-to-head clinical analysis: OXYPHENBUTAZONE versus TANDEARIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXYPHENBUTAZONE versus TANDEARIL.
OXYPHENBUTAZONE vs TANDEARIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxyphenbutazone is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
ACE inhibitor; inhibits angiotensin-converting enzyme, reducing angiotensin II production, leading to vasodilation and decreased aldosterone secretion.
100-200 mg orally 3-4 times daily, not to exceed 600 mg/day.
200 mg orally twice daily with food.
None Documented
None Documented
Terminal elimination half-life ranges from 27 to 64 hours (mean ~50 hours). Prolonged in hepatic or renal impairment; may extend up to 100 hours in elderly.
Clinical Note
moderateOxyphenbutazone + Gatifloxacin
"Oxyphenbutazone may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateOxyphenbutazone + Rosoxacin
"Oxyphenbutazone may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateOxyphenbutazone + Levofloxacin
"Oxyphenbutazone may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateOxyphenbutazone + Trovafloxacin
Terminal elimination half-life is 45 hours, allowing once-daily dosing; steady-state achieved in 7-10 days.
Primarily renal (biliary/fecal minor). Approximately 60-70% excreted in urine as glucuronide conjugates and unchanged drug; 5-10% in feces via bile.
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 35%, with the remainder as metabolites.
Category C
Category C
Nonsteroidal Anti-inflammatory Drug
Nonsteroidal Anti-inflammatory Drug
"Oxyphenbutazone may increase the neuroexcitatory activities of Trovafloxacin."